D. E. Shaw & Co., Inc. Emergent Bio Solutions Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 827,796 shares of EBS stock, worth $7.74 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

827,796

Previous 416,664 98.67%

Holding current value

$7.74 Million

Previous $1.05 Million 435.58%

% of portfolio

0.01%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.86 - $6.98 $764,705 - $2.87 Million	411,132 Added 98.67%	827,796 $5.65 Million
Q1 2024 May 15, 2024	SELL	$1.5 - $3.41 $1.15 Million - $2.63 Million	-769,888 Reduced 64.88%	416,664 $1.05 Million
Q4 2023 Feb 14, 2024	BUY	$1.82 - $3.16 $455,061 - $790,107	250,034 Added 26.7%	1,186,552 $2.85 Million
Q3 2023 Nov 14, 2023	SELL	$3.17 - $7.91 $131,234 - $327,466	-41,399 Reduced 4.23%	936,518 $3.18 Million
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.21 $2.84 Million - $5.1 Million	-385,863 Reduced 28.29%	977,917 $7.19 Million
Q1 2023 May 15, 2023	SELL	$7.79 - $16.29 $2.09 Million - $4.36 Million	-267,838 Reduced 16.42%	1,363,780 $14.1 Million
Q4 2022 Feb 14, 2023	BUY	$11.0 - $21.45 $7.03 Million - $13.7 Million	639,405 Added 64.44%	1,631,618 $19.3 Million
Q3 2022 Nov 14, 2022	SELL	$20.09 - $35.8 $1.48 Million - $2.64 Million	-73,734 Reduced 6.92%	992,213 $20.8 Million
Q2 2022 Aug 15, 2022	SELL	$27.42 - $43.63 $2.68 Million - $4.26 Million	-97,639 Reduced 8.39%	1,065,947 $33.1 Million
Q1 2022 May 16, 2022	BUY	$36.48 - $52.22 $7.96 Million - $11.4 Million	218,248 Added 23.09%	1,163,586 $47.8 Million
Q4 2021 Feb 14, 2022	BUY	$33.11 - $55.01 $29.2 Million - $48.6 Million	882,893 Added 1413.87%	945,338 $41.1 Million
Q3 2021 Nov 15, 2021	BUY	$50.07 - $66.05 $2.65 Million - $3.49 Million	52,852 Added 550.94%	62,445 $3.13 Million
Q2 2021 Aug 16, 2021	BUY	$56.61 - $80.46 $543,059 - $771,852	9,593 New	9,593 $604,000
Q1 2021 May 17, 2021	SELL	$86.23 - $125.19 $1.12 Million - $1.63 Million	-12,991 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$79.17 - $111.47 $1.03 Million - $1.45 Million	12,991 New	12,991 $1.16 Million
Q3 2020 Nov 16, 2020	SELL	$81.91 - $134.94 $651,512 - $1.07 Million	-7,954 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$54.33 - $89.52 $2.05 Million - $3.38 Million	-37,703 Reduced 82.58%	7,954 $629,000
Q1 2020 May 15, 2020	SELL	$49.34 - $68.76 $2.55 Million - $3.55 Million	-51,701 Reduced 53.1%	45,657 $2.64 Million
Q4 2019 Feb 14, 2020	SELL	$51.21 - $59.06 $914,456 - $1.05 Million	-17,857 Reduced 15.5%	97,358 $5.25 Million
Q3 2019 Nov 14, 2019	BUY	$40.6 - $57.2 $3.1 Million - $4.36 Million	76,298 Added 196.05%	115,215 $6.02 Million
Q2 2019 Aug 14, 2019	SELL	$39.92 - $53.86 $1.06 Million - $1.43 Million	-26,555 Reduced 40.56%	38,917 $1.88 Million
Q1 2019 May 15, 2019	SELL	$48.23 - $66.16 $1.69 Million - $2.32 Million	-35,103 Reduced 34.9%	65,472 $3.31 Million
Q4 2018 Feb 14, 2019	SELL	$55.63 - $73.24 $1.39 Million - $1.83 Million	-24,998 Reduced 19.91%	100,575 $5.96 Million
Q3 2018 Nov 14, 2018	SELL	$52.05 - $66.51 $793,970 - $1.01 Million	-15,254 Reduced 10.83%	125,573 $8.27 Million
Q2 2018 Aug 14, 2018	SELL	$48.33 - $55.64 $1.86 Million - $2.14 Million	-38,420 Reduced 21.43%	140,827 $7.11 Million
Q1 2018 May 15, 2018	SELL	$44.44 - $54.39 $2.95 Million - $3.61 Million	-66,332 Reduced 27.01%	179,247 $9.44 Million
Q4 2017 Feb 14, 2018	SELL	$37.77 - $47.75 $1.95 Million - $2.47 Million	-51,702 Reduced 17.39%	245,579 $11.4 Million
Q3 2017 Nov 14, 2017	BUY	$34.14 - $40.45 $10.1 Million - $12 Million	297,281	297,281 $12 Million

Others Institutions Holding EBS

# of Institutions

154

Shares Held

30.3M

Call Options Held

137K

Put Options Held

706K

View Full List

About Emergent BioSolutions Inc.

Ticker EBS
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,861,500
Market Cap $466M
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...

More about EBS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account